Establishing a cohort for non-alcoholic fatty liver disease and developing fibrosis markers
Official title: Establishment of Non-alcoholic Fatty Liver Disease Cohort and Development of Markers to Predict Histologic Progression of Liver Fibrosis
Run by Seoul National University Boramae Hospital · NCT02206841 · Data updated 2026-11-12
This study is trying to gather information from people with non-alcoholic fatty liver disease to see if they can find signs that predict how the disease might worsen over time.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Seoul National University Boramae Hospital Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Seoul) |
| Status | Recruiting |
| Started | January 1, 2014 |
| Main results expected | December 31, 2029 |
| Study ends | December 31, 2030 |
| Registry record updated | May 15, 2025 |
| Trial ID | NCT02206841 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients with histologically or radiologically confirmed non-alcoholic fatty liver disease.
✕Probably not a fit
Patients with significant alcohol consumption, viral hepatitis, autoimmune hepatitis, or other metabolic diseases may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to establish a cohort of patients with non-alcoholic fatty liver disease (NAFLD) to develop markers that can predict the histologic progression of liver fibrosis. The methodology includes various assessments such as acoustic radiation force impulse elastography, transient elastography, liver biopsies, and body composition analysis. Additionally, the study will evaluate pulmonary function, cardiovascular health, and conduct brain imaging and gastrointestinal assessments. The goal is to gather comprehensive data that can lead to better understanding and management of liver fibrosis in NAFLD patients.
Why it matters
Potential benefit: If successful, this study could lead to improved methods for predicting liver fibrosis progression, allowing for earlier interventions in patients with NAFLD.
How similar studies have gone: Other studies have shown promise in developing fibrosis markers for liver diseases, indicating that this approach has potential based on previous findings.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with histologically confirmed fatty liver disease * Patients with radiologically confirmed fatty liver disease Exclusion Criteria: * History of significant alcohol consumption * Viral hepatitis * Autoimmune hepatitis * Metabolic diseases (e.g. hemochromatosis, M. Wilson, alpha 1-antitrypsin deficiency) * Hepatotoxic medication (e.g. amiodarone)
Where it's running
-
Seoul Metropolitan Government Seoul National University
Seoul, South Korea Recruiting
Study contacts
- Principal investigator: Won Kim, Professor — SMG-SNU Boramae Medical Center
- Study coordinator: Won Kim, MD,PhD
- Email: drwon1@snu.ac.kr
- Phone: 8228702233
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Blood biomarker signatures to detect liver fibrosis in chronic liver disease
We will test whether a set of blood biomarkers can show how much liver fibrosis an adult with chronic liver disease has.
-
Endohepatology-based reclassification of treatment indication in high-risk MASLD
This study tests whether an endohepatology assessment can change treatment decisions for adults with high-risk MASLD.
-
Umbilical cord stem cells added during Kasai to help biliary atresia
This early-stage trial tests whether injecting umbilical cord mesenchymal stem cells during Kasai portoenterostomy is safe and helpful for infants with biliary atresia.
-
Automated Passive Case-Finding for Advanced Liver Fibrosis in MASLD
This program automatically screens high‑risk adults aged 50–75 in primary care to see if they have advanced liver fibrosis and possible MASLD, using routine blood tests and reflex lab tests without extra work for clinicians.
-
AZD2389 safety and dosing in adults with fatty liver disease and advanced liver scarring
This study tests whether AZD2389 is safe and how it behaves in adults with steatotic liver disease and advanced fibrosis, comparing it to placebo over about six months.
-
See if EUS-SWQ can accurately detect and grade liver fibrosis in adults with chronic liver disease
This study tests whether the endoscopic ultrasound shear wave quantification (EUS-SWQ) can match liver biopsy results in adults with chronic liver disease to diagnose and stage fibrosis, and whether it offers safety and measurement advantages over FibroScan.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.